Nuvation Bio Inc
For the period ended Mar 31, 2024. Filed May 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 14, 2024
NUVB$4.20-3.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Cash Flows
(Unaudited, In thousands)
| For the Three Months Ended March 31, | 2024 | 2023 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | $(14,792) | $(21,726) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 5,041 | 4,837 |
| Depreciation and amortization | 58 | 56 |
| Non-cash lease expense | (38) | (17) |
| Change in fair value of warrant liability | 1,459 | (142) |
| Net amortization on marketable securities | (2,820) | (2,147) |
| Net (gain) loss on marketable securities | (1) | 96 |
| Net loss on disposal of property and equipment | — | 12 |
| Change in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (5,277) | 137 |
| Interest receivable on marketable securities | (581) | 212 |
| Other non-current assets | (488) | — |
| Accounts payable | 227 | 806 |
| Accrued expenses | 1,510 | (1,454) |
| Net cash used in operating activities | (15,702) | (19,330) |
| Cash flow from investing activities: | ||
| Purchases of marketable securities | (128,409) | (236,967) |
| Proceeds from sale of marketable securities | 135,978 | 184,983 |
| Purchases of property and equipment | (27) | (12) |
| Net cash provided by (used in) investing activities | 7,542 | (51,996) |
| Cash flow from financing activities: | ||
| Proceeds from exercises of options | 21 | 298 |
| Net cash provided by financing activities | 21 | 298 |
| Net decrease in cash and cash equivalents | (8,139) | (71,028) |
| Cash and cash equivalents, beginning of the period | 42,649 | 101,099 |
| Cash and cash equivalents, end of the period | $34,510 | $30,071 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.